New approach in bioavailability study of two formulations of ethyl loflazepate.
The disposition of ethyl loflazepate (Victan) was studied on 12 healthy male volunteers after administration of the two oral formulations of the drug: one 4-mg tablet and two 2-mg tablets according to an open crossover single dose comparison. A model-independent analysis and a model-dependent approach were used to treat experimental data. Appropriate statistical tests (ANOVA, Wilcoxon test, Westlake test for model-independent parameters; principal components analysis, Hotelling T2 test for model-dependent parameters) demonstrated the bioequivalence of the two formulations.
Ba
B B
BB
INSERM U 278, Faculty of Pharmacy, Marseille, France.
Iliadis
A
A
Durand
A
A
Berger
Y
Y
Cano
J P
JP
D000284:Administration, Oral; D000328:Adult; D014151:Anti-Anxiety Agents / Q000008:administration & dosage / Q000493:pharmacokinetics*; D001569:Benzodiazepines; D001570:Benzodiazepinones / Q000008:administration & dosage / Q000493:pharmacokinetics*; D001682:Biological Availability; D006801:Humans; D008297:Male; D008433:Mathematics; D008954:Models, Biological
D014151:Anti-Anxiety Agents; D001570:Benzodiazepinones; D001569:Benzodiazepines; C029617:ethyl loflazepate